Jianpi Zhixie Powder Veterinary Grade API is supplied as a brown-yellow to tan fine powder with a characteristic botanical odor. It is intended for further processing into tablets, capsules, powders, granules, premixes, oral solutions, and—after extraction, purification, and depyrogenation—parenteral intermediates. The product does not carry a harmonized commercial model designation. Manufacturer drug master files assign internal codes that vary by dosage-form compatibility, such as suffix -T for tablet grade, -C for capsule grade, -G for granule grade, -P for premix grade, -S for oral solution grade, and -I for injection-grade extract. The suffix alone is not a regulatory guarantee. Injection grade must be confirmed by bacterial endotoxin testing, validated purification history, and residual solvent control under the relevant veterinary registration file.

The botanical identity is based on the multi-herb whole powder profile. Atractylodes macrocephala rhizome, Poria cocos sclerotium, and Dioscorea opposita rhizome are typically present, with additional species described in the pharmacopoeial monograph. Analytical targets include the triterpenoid marker atractylenolide III and total water-soluble polysaccharides. Thin-layer chromatography, microscopic characterization of starch granules and fungal hyphae, and organoleptic examination are used because the powder does not contain a single pharmacologically dominant molecule. This multi-marker identity creates a characteristic fingerprint but also complicates assay standardization relative to synthetic single-molecule veterinary APIs.

Which specification parameters govern batch release for a multi-route botanical API?

Release for multiple downstream dosage forms requires a combined pharmacopoeial and process-specific specification. Published numeric harmonization for all attributes is limited. The values in Table 1 are representative industrial release limits compiled from GMP dossiers for polysaccharide-rich botanical APIs of this class. They are not a substitute for the current pharmacopoeial monograph or the approved veterinary drug registration file.

At production scale, the largest source of batch variance is not the assay method but particle-size distribution and moisture of incoming botanical lots. Warehousing under uncontrolled humidity has produced caking and false-positive Salmonella enrichment due to post-milling moisture migration in bulk bags. A pre-milling drying step at 55-60°C is therefore imposed when ambient relative humidity exceeds 60% at the mill intake. Lot synthesis is performed in a double-cone blender of 500-1000 L capacity. The filled volume is maintained at 60-70% of rated capacity because axial segregation of fibrous and starchy particles occurs at fill volumes below 40%. Batch records require sampling from top, middle, and bottom using a grain thief after 15 min of tumbling.

The absence of a universal model number creates a traceability burden. Contract analytical laboratories and formulators should require the supplier’s certificate of analysis to state the monograph name, internal product code, milling train, botanical lot numbers, and storage conditions from harvest to dispatch. If injection grade is intended, the certificate must additionally state the purification route, bacterial endotoxin limit, and residual solvent data under VICH GL18.

When high-polysaccharide botanical powder is milled below 150 μm

Tablets are the most demanding route. Direct compression is not recommended for untreated powder because the high polysaccharide fraction creates a cohesive, poorly flowing matrix with Carr index above 30%. Field measurements on powder-rheology testers indicate conditioned bulk density of 0.45-0.55 g/cm³ and basic flowability energy in the cohesive regime. In a 27-station rotary press campaign, untreated powder with moisture above 9.0% adhered to upper punch faces within 40-60 min at 35,000 tablets/h, producing weight variation outside the dosage-form monograph limit. The corrective action was fluid-bed granulation with 2.5-5.0 wt% povidone K30 as binder and 0.5 wt% croscarmellose sodium as disintegrant.

Granulation inlet air temperature was set at 55-65°C, product temperature at 35-45°C, and final granule loss on drying at 3.0-5.0%. Compression force for 8 mm flat-faced beveled D-tooling was maintained at 8-15 kN, with tablet hardness of 30-60 N. Hardness above 80 N was rejected because disintegration exceeded 30 min in water at 37°C. Tooling was specified as D-tooling with chromium nitride coating and punch tip polish of 0.1 μm Ra or better to reduce picking during long runs.

Capsule filling is less demanding than tableting but still requires moisture control at ≤ 6.0% and the addition of 0.5-1.0 wt% colloidal silicon dioxide for size 0 capsule fills of 300-500 mg. Powders and premixes require geometric dilution in a ribbon blender for 15-20 min. Release of a 10 g sample should show content uniformity with coefficient of variation not more than 5.0%. Fluid-bed top-spray granulation is run at an inlet temperature of 50-60°C, with a spray rate of 10-20 g/min per kg of powder for a 2.0-5.0 wt% binder solution. The process is stopped at 3.0-5.0% loss on drying.

Injection use requires a fundamentally different downstream route. The raw powder is not injectable. Aqueous extraction is performed at 80-90°C for 60-120 min, followed by centrifugation at 8,000-10,000 × g and sequential filtration through 0.45 μm and 0.22 μm polyethersulfone membranes. Polysaccharide-rich extracts above 2.0% w/v display rapid flux decline on 0.22 μm membranes and require either feed temperatures of 40-50°C or a pre-filtration step with diatomaceous earth. Endotoxin control is validated by the kinetic chromogenic LAL method of USP <85>. Raw botanical powder frequently carries endotoxin loads well above the parenteral limit. The purification route must demonstrate at least 2-3 log10 endotoxin reduction. Published data for this specific Jianpi Zhixie injection configuration is limited, and each manufacturer must validate the extractable marker profile after purification.

Oral solutions are prepared as aqueous dispersions at 40-50°C with pH 5.0-6.5. Solution concentrations above 5.0% w/v exhibit viscosity greater than 100 mPa·s; high-torque overhead stirring and inline homogenization may be needed. Organic co-solvents should be avoided unless compatibility with polysaccharide precipitation has been tested. Extraction for concentrated solutions uses a water-to-herb ratio of 8:1 to 12:1 v/w. Ethanol concentrations above 30% v/v precipitate high-molecular-weight polysaccharides and alter the polysaccharide-to-triterpenoid marker ratio. This may be acceptable for some capsule granules but not for solutions intended to retain polysaccharide viscosity.

Batch-to-batch variance in commercial milling campaigns is observed primarily in the fines fraction below 74 μm. Coarse starch granules from Dioscorea opposita and hyphal fragments of Poria cocos segregate in low-shear mixers unless the fines are reincorporated by geometric dilution. In one campaign, a 500 kg batch milled through a hammer mill with a 0.5 mm screen showed a fines fraction of 18-22% w/w. Direct sampling after drum filling differed by 8-12% in atractylenolide III concentration between top and bottom. A post-mill conical screw mixer operating at 12 rpm for 20 min reduced the coefficient of variation to below 3.0% in 500 g samples. This field pattern justifies post-milling blending rather than relying on mill output directly.

Residue Chemistry and Differential Advantages Against Synthetic Antidiarrheal APIs

The API differs from single-molecule veterinary antidiarrheal substances such as colistin sulfate, enrofloxacin, amoxicillin trihydrate, and zinc oxide in composition, mechanism, standardization, and residue behavior. Synthetic molecules are typically assayed to a clear pharmacopoeial potency limit and can be quantified in plasma and edible tissues. This botanical powder is standardized to marker and total polysaccharide content rather than a single active ingredient. The whole-herb multi-component composition may exert physical protective effects in the intestinal tract and microbial ecosystem modulation, but its efficacy in acute bacterial enteritis is not supported by the same randomized clinical data expected for registered antibiotics. The product is therefore positioned as a supportive or adjunctive antidiarrheal preparation, and veterinary prescription decisions should separate functional diarrhea management from antibacterial therapy.

Operational boundaries are relevant for formulation development. The powder should be pre-dried when ambient relative humidity exceeds 60% and protected from moisture ingress in sealed polyethylene-lined kraft bags. Accelerated stability studies for botanical powders of this class typically use 40°C ± 2°C and 75% ± 5% relative humidity for 6 months per VICH GL3. Under uncontrolled 75% relative humidity, caking can occur within 48 h. A desiccant-to-product ratio of 1:10 by mass is often used for bulk drums, but this must be validated by sorption isotherm data.

Liquid formulations should be held at pH 5.0-6.5 because prolonged exposure to pH below 3.0 or above 8.0 hydrolyzes polysaccharides and shifts the chromatographic fingerprint. Strong oxidizing agents and concentrated mineral acids are incompatible. For parenteral use, terminal steam sterilization of the finished herbal solution is not recommended where polysaccharide color and viscosity stability have not been validated. Aseptic filtration after depyrogenation is the default route if the product is registered as an injection. The absence of published species-specific withdrawal periods for this botanical mixture means that use in food-producing animals must be assessed by the relevant regional residue authority before administration.